Dynavax Technologies Corp
Closed
SectorHealthcare
15.49
Overview
Share price change
24h
Min
15.49
Max
15.49
Income | 8.2M 27M |
|---|---|
Sales | -566K 95M |
Profit margin | 28.381 |
Employees | 405 |
EBITDA | 7M 32M |
Next Earnings | 19 lut 2026 |
|---|
Market Cap | 625M 1.8B |
|---|---|
Previous open | 15.49 |
Previous close | 15.49 |
News Sentiment
By Acuity
18%
82%
26 / 352 Ranking in Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Dynavax Technologies Corp Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Dynavax Technologies Corp Forecast
Sentiment
By Acuity
26 / 352 Ranking in Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Dynavax Technologies Corp
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.
